Aart Beeker

3.0k total citations
56 papers, 1.1k citations indexed

About

Aart Beeker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Aart Beeker has authored 56 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 10 papers in Genetics. Recurrent topics in Aart Beeker's work include Prostate Cancer Treatment and Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Cancer Treatment and Pharmacology (8 papers). Aart Beeker is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), Lymphoma Diagnosis and Treatment (9 papers) and Cancer Treatment and Pharmacology (8 papers). Aart Beeker collaborates with scholars based in Netherlands, Australia and United Kingdom. Aart Beeker's co-authors include Aeilko H. Zwinderman, Ron A. A. Mathôt, Cornelis J.A. Punt, Mariëtte J. Weterman, Sil Kordes, Johanna W. Wilmink, Michaël Pollak, Dick J. Richel, Henk M.W. Verheul and Maartje Los and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Aart Beeker

55 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aart Beeker Netherlands	18	452	344	289	228	211	56	1.1k
Ami V. Desai United States	18	250 0.6×	278 0.8×	229 0.8×	195 0.9×	111 0.5×	52	1.0k
Kun‐Ming Rau Taiwan	20	459 1.0×	302 0.9×	350 1.2×	183 0.8×	162 0.8×	65	1.3k
Hung Chang Taiwan	18	252 0.6×	217 0.6×	144 0.5×	65 0.3×	254 1.2×	98	1.0k
Jae‐Cheol Jo South Korea	20	682 1.5×	306 0.9×	300 1.0×	64 0.3×	469 2.2×	134	1.4k
Ru Feng China	17	319 0.7×	158 0.5×	198 0.7×	88 0.4×	373 1.8×	93	998
Luigi De Sio Italy	21	357 0.8×	238 0.7×	472 1.6×	61 0.3×	153 0.7×	39	1.2k
Anders Själander Sweden	24	452 1.0×	307 0.9×	85 0.3×	147 0.6×	117 0.6×	81	1.9k
Phuong K. Morrow United States	24	1.0k 2.3×	525 1.5×	396 1.4×	283 1.2×	181 0.9×	65	1.8k
Abdurrahman Işıkdoğan Türkiye	19	537 1.2×	204 0.6×	424 1.5×	186 0.8×	146 0.7×	146	1.2k
Yan Song United States	20	613 1.4×	419 1.2×	435 1.5×	206 0.9×	104 0.5×	132	1.5k

Countries citing papers authored by Aart Beeker

Since Specialization

Citations

This map shows the geographic impact of Aart Beeker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aart Beeker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aart Beeker more than expected).

Fields of papers citing papers by Aart Beeker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aart Beeker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aart Beeker. The network helps show where Aart Beeker may publish in the future.

Co-authorship network of co-authors of Aart Beeker

This figure shows the co-authorship network connecting the top 25 collaborators of Aart Beeker. A scholar is included among the top collaborators of Aart Beeker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aart Beeker. Aart Beeker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jonge, Nick de, Jeroen J. W. M. Janssen, Paula F. Ypma, et al.. (2024). Mucositis-associated bloodstream infections in adult haematology patients with fever during neutropenia: risk factors and the impact of mucositis severity. Supportive Care in Cancer. 32(9). 579–579. 2 indexed citations

Zande, Kim van der, Paul Hamberg, Annegien Broeks, et al.. (2024). Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy. Clinical Genitourinary Cancer. 22(2). 445–453.e1. 2 indexed citations

Bromberg, Jacoline E. C., Samar Issa, Bronno van der Holt, et al.. (2023). Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study. Neuro-Oncology. 26(4). 724–734. 5 indexed citations

Groen, Kevin, Marjolein L. Donker, K.G. van der Hem, et al.. (2023). Treatment sequences and drug costs from diagnosis to death in multiple myeloma. European Journal Of Haematology. 112(3). 360–366. 1 indexed citations

Duhoux, François P., Nuhad K. Ibrahim, J-L. Canon, et al.. (2023). 255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization. ESMO Open. 8(1). 101443–101443. 1 indexed citations

Werf, A. van der, J.A.E. Langius, Aart Beeker, et al.. (2020). The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial. Clinical Nutrition. 39(10). 3005–3013. 39 indexed citations

Meulen, Matthijs van der, Katerina Bakunina, Marcel Nijland, et al.. (2020). Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. Annals of Oncology. 31(8). 1046–1055. 4 indexed citations

Retz, Margitta, Jens Bedke, Martin Bögemann, et al.. (2018). SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). European Journal of Cancer. 107. 37–45. 21 indexed citations

Retz, Margitta, Jens Bedke, Eva Herrmann, et al.. (2017). Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II). Annals of Oncology. 28. v295–v295. 17 indexed citations

10.

Jong, Joyce M. van Dodewaard-de, John M. H. de Klerk, Haiko J. Bloemendal, et al.. (2017). A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. European Journal of Nuclear Medicine and Molecular Imaging. 44(8). 1319–1327. 16 indexed citations

11.

Nieuweboer, Annemieke J.M., Anne‐Joy M. de Graan, Paul Hamberg, et al.. (2016). Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study. Clinical Cancer Research. 23(7). 1679–1683. 12 indexed citations

12.

Houtenbos, Ilse, Jan Paul de Boer, Aart Beeker, et al.. (2016). Diffuse large B-cell lymphoma with MYC gene rearrangements. European Journal of Cancer. 55. 140–146. 15 indexed citations

13.

Timmers, Lonneke, Christel C. L. M. Boons, Peter M. van de Ven, et al.. (2016). Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. Frontiers in Pharmacology. 7. 310–310. 21 indexed citations

14.

Kroep, Judith R., Erik van Werkhoven, Marco B. Polée, et al.. (2015). Randomised study of tegafur–uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer — TLC study. Journal of Geriatric Oncology. 6(4). 307–315. 15 indexed citations

15.

Kordes, Sil, Michaël Pollak, Aeilko H. Zwinderman, et al.. (2015). Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. The Lancet Oncology. 16(7). 839–847. 300 indexed citations

16.

Wever, Kimberley E., Jan Hein van Waesberghe, Aart Beeker, et al.. (2015). What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study. Cancer Epidemiology. 39(6). 848–853. 7 indexed citations

17.

Neefjes, Elisabeth C. W., W. W. A. Zuurmond, Hans van Vliet, et al.. (2014). Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliative Care. 13(1). 42–42. 13 indexed citations

18.

Veeger, Nic J.G.M., Marinus van Marwijk Kooy, Aart Beeker, et al.. (2013). Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leukemia Research. 37(8). 877–882. 24 indexed citations

19.

Wumkes, M.L., Ankie M.T. van der Velden, Maartje Los, et al.. (2013). Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine. 31(52). 6177–6184. 36 indexed citations

20.

Meerveld-Eggink, A., Okke de Weerdt, Ankie M.T. van der Velden, et al.. (2011). Response to influenza virus vaccination during chemotherapy in patients with breast cancer. Annals of Oncology. 22(9). 2031–2035. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact